Researchers from a number of public health agencies in France took on the task of identifying phenotypes in infants. The results of their study indicate that early respiratory symptoms predict asthma at 1 year.
Various phenotypes seem to respond differently to interventions and medication, prompting the utility of determining a patient's asthma phenotype to become a current research priority. Researchers have conducted the lion's share of research in older children and adults, and little information has been available about asthma phenotypes in infants. Researchers from a number of public health agencies in France took on the task of identifying phenotypes in infants. The results of their study, recently published in the journalPLoS One, indicate that early respiratory symptoms predict asthma at 1 year.
Healthcare providers, and parents identify wheezing in approximately 25% to 30% of infants. Its etiology is often difficult to trace, as environmental exposure (including parental smoking), and viral infection can cause wheezing. When wheezing is associated with asthma, it protects reduced respiratory function, and accelerated lung function decline in later life. For this reason, these researchers were eager to find factors that could predict asthma. A study strength is at the researchers looked at more than 18,000 infants over the course of their first year. They identifed 4 specific phenotypes:
This study found that children who experienced nocturnal cough, signs of respiratory distress, and excess bronchial secretion, and whose symptoms continued to increase from age 2 months to 1 year, were at elevated risk for persistent wheezing.
They also linked maternal smoking with persistent wheezing, and incident wheezing at one year. They note that children born to women who smoke tend to have narrower airways than others. This may contribute to wheezing. A mother's history of hay fever, eczema or asthma also increase the likelihood of persistent wheezing in children.
This article was originally published atPharmacyTimes.com.
Reference
Hallit S, Leynaert B, Delmas MC, et al. Wheezing phenotypes and risk factors in early life: The ELFE cohort.PLoS One. 2018;13(4):e0196711.
FDA Approves Omalizumab to Reduce Food-Based Allergic Reactions in Adult and Pediatric Patients
February 21st 2024This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.